Compass Pathways’ psilocybin treatment shows lasting benefits in treatment-resistant depression

Compass Pathways plc CMPS on Wednesday shared topline 52-week Part C results from its Phase 3 COMP005 study evaluating ...
TMCnet

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to ...
InvestorsHub on MSN

Compass Pathways reports 52-week Phase 3 COMP005 results for COMP360

Compass Pathways plc (NASDAQ:CMPS) reported 52-week topline results from Part C of its Phase 3 COMP005 trial evaluating ...

Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training

Fluence, a leading provider of professional education in psychedelic therapy, today announced that it has been selected by Compass Pathways plc (Nasdaq: CMPS) as a recipient of its U.S. healthcare ...
TMCnet

Compass Pathways to Participate in Investor Conferences the Week of September 14th

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will participate in the ...
Agence France-Presse

Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the topline 52-week results (Part C) ...
Agence France-Presse

Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced its participation at Psych Congress ...
Seeking Alpha

COMPASS Pathways Plc (CMPS) Presents At Cantor Global Healthcare Conference 2025 Transcript

All right. Welcome, everyone. We're going to get started. I'm Josh Schimmer from the Cantor Biotech Equity Research team. Very pleased to introduce from the COMPASS Pathways. We have the management ...
Yahoo Finance

Why COMPASS Pathways plc (CMPS) Draws Both Optimism and Caution

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Compass Pathways Forecast: Breakout Could Target $22.51–$25.51

CMPS is testing a breakout after positive Phase 3 data, with a close above $15.40 potentially opening the way toward ...
Seeking Alpha

COMPASS Pathways plc (CMPS) Discusses Clinical Trial Plans for PTSD and Commercial Preparations for Treatment-Resistant Depression Transcript

Myriam Barthes - Journey Clinical, Inc. Good day, ladies and gentlemen, and welcome to this COMPASS Pathways update webinar. [Operator Instructions] As a reminder, this call is being recorded. I would ...
The Motley Fool

Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.

Some of the most important upcoming catalysts for Compass' stock have little to do with its own research and development (R&D) or business development activities. Lykos Therapeutics, a psychedelic ...